Neurocrine Biosciences

NBIXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$16.224 B

$160.29 -3.47%

Close of 6 Nov 2026

As of 6 Nov 2026, Neurocrine Biosciences (NBIX) has a market capitalization of $16.2B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$2.86B

#946 by revenue

Earnings

$478.6M

#627 by earnings

Shares outstanding

101,218,643

Latest filing cover page

P/E ratio

33.9

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#7BioNTech SEBNTX$21.6B
#8ExelixisEXEL$16.8B
#9Neurocrine BiosciencesNBIX$16.2B
#10Halozyme TherapeuticsHALO$14.0B
#11Bio-TechneTECH$11.4B

What if Neurocrine Biosciences were worth as much as…

Open the what-if tool →

Gold $28.2T

$278,969.10

Per share 1,740× higher

Bitcoin $1.53T

$15,094.53

Per share 94.2× higher

Apple $5.02T

$49,553.94

Per share 309× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Neurocrine Biosciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.